Takeda Pharmaceutical Company Limited Stock price

Equities

4502

JP3463000004

Pharmaceuticals

Delayed Japan Exchange 10:14:28 2024-03-18 pm EDT 5-day change 1st Jan Change
4,356 JPY -0.11% Intraday chart for Takeda Pharmaceutical Company Limited +1.82% +7.45%
Sales 2024 * 4,062B 27.23B Sales 2025 * 3,990B 26.75B Capitalization 6,842B 45.87B
Net income 2024 * 140B 938M Net income 2025 * 236B 1.58B EV / Sales 2024 * 2.61 x
Net Debt 2024 * 3,763B 25.23B Net Debt 2025 * 3,429B 22.99B EV / Sales 2025 * 2.57 x
P/E ratio 2024 *
47.5 x
P/E ratio 2025 *
29.2 x
Employees 49,095
Yield 2024 *
4.31%
Yield 2025 *
4.35%
Free-Float 99.11%
More Fundamentals * Assessed data
Dynamic Chart
Takeda Pharmaceutical Says Mezagitamab Phase 2 Trial Shows 'Positive' Results in Primary Immune Thrombocytopenia Patients MT
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia CI
Toyota becomes Asia's most shorted large-cap stock - Hazeltree RE
India's Serum looks beyond COVID with new vaccines for malaria, dengue RE
EARNINGS: Hutchmed revenue surges, Craven House's loss widens AN
Takeda Pharmaceutical Teams Up With Biological E. to Boost Production of Dengue Vaccine MT
HEDGEFLOW - Japan enthusiasm driving inflows to US-listed Asian equities, Morgan Stanley says RE
Japan's Takeda partners with India's Biological E. to boost dengue vaccine production RE
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas CI
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,600 Yen From 5,200 Yen, Keeps at Buy MT
Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited CI
Sector Update: Health Care Stocks Mixed Pre-Bell Monday MT
Takeda Pharmaceutical Says US FDA Approves Eohilia as Eosinophilic Esophagitis Treatment MT
US FDA approves Takeda's therapy for allergic inflammation in esophagus RE
FDA Approves Takeda's EOHILIA (budesonide Oral Suspension) CI
More news

Latest transcript on Takeda Pharmaceutical Company Limited

1 day+1.37%
1 week+0.21%
Current month-0.59%
1 month-1.16%
3 months+9.16%
6 months-10.27%
Current year+7.57%
More quotes
1 week
4 248.00
Extreme 4248
4 377.00
1 month
4 248.00
Extreme 4248
4 494.00
Current year
4 084.00
Extreme 4084
4 494.00
1 year
3 900.00
Extreme 3900
4 873.00
3 years
2 993.00
Extreme 2993
4 873.00
5 years
2 894.50
Extreme 2894.5
4 873.00
10 years
2 894.50
Extreme 2894.5
6 693.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 14-03-31
Director of Finance/CFO 52 14-12-31
Chief Tech/Sci/R&D Officer 45 22-01-31
Members of the board TitleAgeSince
Director/Board Member 71 16-05-31
Director/Board Member 62 18-12-31
Director/Board Member 70 18-12-31
More insiders
Date Price Change Volume
24-03-18 4,356 -0.11% 1 553 800
24-03-18 4,361 +1.37% 4,078,300
24-03-15 4,302 +0.33% 5,527,400
24-03-14 4,288 +0.33% 3,947,600
24-03-13 4,274 -0.09% 4,267,700

Delayed Quote Japan Exchange, March 18, 2024 at 02:00 am EDT

More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,361 JPY
Average target price
4,784 JPY
Spread / Average Target
+9.71%
Consensus
  1. Stock
  2. Equities
  3. Stock Takeda Pharmaceutical Company Limited - Japan Exchange